Home

Recent Articles from GlobeNewswire

Ancestral sacrifice held in Chinese Yan Emperor's hometown Suizhou
SUIZHOU, China, May 23, 2025 (GLOBE NEWSWIRE) -- A grand ancestral worship festival in the hometown of Chinese Yan Emperor was held in Suizhou, central China's Hubei Province, on May 23.
Together for Better Liver Health: WHA78 Side Event Unites Global Stakeholders to Strengthen Public Health Responses to Metabolic Disease
Geneva, Switzerland, May 23, 2025 (GLOBE NEWSWIRE) -- Global health leaders call for urgent, integrated action on the rising rates of metabolic liver disease during a high-level policy event held on the sidelines of the 78th World Health Assembly and co-hosted by Global Liver Institute (GLI), the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). This event brought together leading experts, policymakers, public health officials, and advocates to push for stronger public health strategies that address liver disease as part of the global noncommunicable diseases (NCDs) response and highlight the need to embed liver health within national NCD strategies.
By Global Liver Institute · Via GlobeNewswire · May 23, 2025
‘Pub Delivery’: Heineken® brings fans’ matchday ritual – and their ‘lucky pub’ - with them to Lisbon for the UEFA Women’s Champions League final
By Heineken · Via GlobeNewswire · May 23, 2025
Inventiva reports 2025 First Quarter Financial Information¹
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues.
By INVENTIVA · Via GlobeNewswire · May 23, 2025
Bitget and Cryptita Plays Inspire Next Generation with Young Learners' Encyclopedia
By Bitget Limited · Via GlobeNewswire · May 23, 2025
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting.  
By INVENTIVA · Via GlobeNewswire · May 23, 2025
Pricing of Senior Secured Notes
 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE IT IS UNLAWFULTO DO SO
By Flutter Entertainment PLC · Via GlobeNewswire · May 23, 2025
Endeavour Announces Results of Annual General Meeting 2025
ENDEAVOUR ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING 2025
By Endeavour Mining PLC · Via GlobeNewswire · May 23, 2025
FRO – First Quarter 2025 Results
FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025
By Frontline plc. · Via GlobeNewswire · May 23, 2025
Youth sports exchange to bridge cultures, strengthen ties
The 2025 Belt and Road Youth Sports Exchange Week (Jiangsu)
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025
By OSE Immunotherapeutics · Via GlobeNewswire · May 23, 2025
Aurio Expands Integrated Business Services Portfolio with New Finance Operations Segment
Cherry Hill, NJ, May 23, 2025 (GLOBE NEWSWIRE) -- Aurio, an innovative business services company, has expanded its offerings with the launch of a new Finance Operations segment, delivering a full finance stack to help clients manage financial performance with a strategic focus. The segment, which debuted last month, offers a comprehensive suite of financial services, including bookkeeping, finance operations consulting, and CFO services.
By Aurio · Via GlobeNewswire · May 23, 2025
De Havilland Canada announces the expansion of its presence in Greece
ATHENS, Greece, May 23, 2025 (GLOBE NEWSWIRE) -- De Havilland Aircraft of Canada Limited (“De Havilland Canada”) is pleased to announce the launch of De Havilland Aircraft of Canada Hellas Ltd., its new wholly-owned subsidiary in Greece, further strengthening our commitment to providing exceptional customer support to our valued customers in the region. This expansion also reflects De Havilland Canada’s deep confidence in the Greek market and its strong cooperation with the Greek government and the relevant aviation authorities.
Bitget Wallet Launches New Brand Identity and "Crypto for Everyone" Movement
Backed by 300% user growth, Bitget Wallet unveils a new design and $1M campaign to bring crypto into everyday use worldwide
By Bitget Limited · Via GlobeNewswire · May 22, 2025
ADTRAN ALERT: Bragar Eagel & Squire, P.C. is Investigating ADTRAN Holdings, Inc. on Behalf of ADTRAN Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against ADTRAN Holdings, Inc. (“ADTRAN” or the “Company”) (NASDAQ:ADTN) on behalf of ADTRAN stockholders. Our investigation concerns whether ADTRAN has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
SEMLER ALERT: Bragar Eagel & Squire, P.C. is Investigating Semler Scientific Inc. on Behalf of Semler Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Semler Scientific Inc. (“Semler” or the “Company”) (NASDAQ:SMLR) on behalf of Semler stockholders. Our investigation concerns whether Semler has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30, 2024 to January 8, 2025. Our investigation concerns whether the board of directors of Intellia have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
APPLE ALERT: Bragar Eagel & Squire, P.C. is Investigating Apple Inc. on Behalf of Apple Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apple Inc. (“Apple” or the “Company”) (NASDAQ:AAPL) on behalf of Apple stockholders. Our investigation concerns whether Apple has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
LUNA INNOVATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Luna Innovation, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Luna Innovation, Inc. (OTC: LUNA) on behalf of long-term stockholders following a class action complaint that was filed against Luna Innovation on April 1, 2024 with a Class Period from August 11, 2023 to March 25, 2024. Our investigation concerns whether the board of directors of Luna Innovation have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds of the offering to Gyre, before deducting the underwriting discounts and commissions and other offering expenses payable by Gyre, are expected to be approximately $20.0 million. The offering is expected to close on or about May 27, 2025, subject to the satisfaction of customary closing conditions.
By Gyre Therapeutics Inc. · Via GlobeNewswire · May 22, 2025
CECOCECO to Unveil ArtMorph Innovation at AIA Conference on Architecture & Design 2025
BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- CECOCECO, a leading innovator in the lighting and display industry, is excited to announce its participation in the AIA Conference on Architecture & Design 2025, taking place from June 4-7 in Boston. At Booth #1119, CECOCECO will present the latest edition of ArtMorph—an innovative luminous wall panel that seamlessly blends LED display technology with textures.
By CECOCECO CO., LTD · Via GlobeNewswire · May 22, 2025
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today announced that new clinical data from two ongoing investigational studies evaluating lisaftoclax in various blood cancers and alrizomadlin in solid tumors will be presented during an oral presentation and poster presentation, respectively, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 - June 3 in Chicago, Ill., USA. Both lisaftoclax and alrizomadlin demonstrated antitumor activity, and the data support their further clinical development.
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA.
By HUTCHMED (China) Limited · Via GlobeNewswire · May 22, 2025
ZEBRA Launches THE LIP GLOSS - CLEAR, Continuing Its Mission to Deliver Elevated Non-Toxic Personal Care
Dallas, TX, May 22, 2025 (GLOBE NEWSWIRE) -- ZEBRA, the personal care brand founded by clean wellness advocate Jenn Thatcher, has officially expanded into the beauty space with the launch of THE LIP GLOSS - CLEAR, a high-shine, non-toxic gloss designed for long-lasting hydration and a mirror-like finish.
By ZEBRA · Via GlobeNewswire · May 22, 2025
Entertainment Without Borders: AI-Media and Lightning International Join Forces to Make FAST Channels Accessible to Everyone
SYDNEY and HONG KONG, May 22, 2025 (GLOBE NEWSWIRE) -- AI-Media Technologies Limited ("AI-Media"), a global leader in live captioning and translation solutions, has entered a groundbreaking partnership with Lightning International ("Lightning"), the leading distributor of Free Ad-Supported Television (FAST) channels. This collaboration aims to break down barriers and bring the joy of entertainment to every corner of the globe, and enhance revenue opportunities for FAST platforms and content owners, transforming how premium content is distributed and monetized across diverse markets.
By Ai-Media Technologies LLC · Via GlobeNewswire · May 22, 2025
Pepsi Follows Coca-Cola’s Lead and Abandons Reuse Goal, Doubling Down on Single-Use Plastic Packaging
WASHINGTON, May 22, 2025 (GLOBE NEWSWIRE) -- On May 22, PepsiCo announced it is abandoning its reuse goal: to achieve 20% of all beverage servings the company sells be sold through reusable models by 2030. In addition, the company ended its goal to “cut virgin plastic from non-renewable sources per serving” and scaled back other goals related to its plastic packaging use. PepsiCo reported in 2023 that the company’s share of packaging in reusable formats was 10%, unchanged from when it first announced its goal in 2022.
By Oceana, Inc. · Via GlobeNewswire · May 22, 2025
For the First Time in Dubai Two Restaurants are Awarded Three MICHELIN Stars
DUBAI, United Arab Emirates, May 23, 2025 (GLOBE NEWSWIRE) -- Michelin celebrated the city's culinary excellence like never before at Dubai’s fourth MICHELIN Guide Ceremony, held at Address Sky View. The event revealed 119 establishments, covering over 35 cuisine types, which made it into this year’s selection, showcasing the city’s booming gastronomic scene.
By Michelin AIM FZCO · Via GlobeNewswire · May 22, 2025
Bunker Hill Announces Increase to the Previously Announced Promissory Note to Ensure Sufficient Liquidity as it Continues Toward Closing its Private Placements and Major Capital Restructuring
KELLOGG, Idaho and VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corp. (“Bunker Hill” or the “Company”) (TSX-V: BNKR |OTCQB: BHLL) is pleased to announce that the Company and Teck Resources Limited (“Teck”) have agreed to amend and restate the unsecured promissory note previously provided by Teck to increase the maximum aggregate principal amount thereunder from US$3.4 million to US$4.4 million (as amended and restated, the “Promissory Note”). The Promissory Note ensures sufficient short-term funding until the previously announced brokered and non-brokered private placements close, and bears interest at a rate of 12% per annum, with such interest being capitalized and added to the principal amount outstanding monthly under the Promissory Note. The Promissory Note is available in multiple advances, at the discretion of Teck, and is payable by the Company in cash on demand from Teck. No bonus securities of the Company will be issued to Teck in connection with the Promissory Note, nor is the Promissory Note convertible into securities of the Company.
By Bunker Hill Mining Corp. · Via GlobeNewswire · May 22, 2025
KBR Announces Intent to Build Human Spaceflight Innovation Facility at ACMI Properties’ Exploration Park, Supporting Missions to Mars, the Moon, and In-Orbit
Global leader in human spaceflight and aerospace services to operate a 45,000-square-foot astronaut food innovation facility at Exploration Park on NASA’s Johnson Space Center
By ACMI Group · Via GlobeNewswire · May 22, 2025
The Coastal Companies Issues Voluntary Recall on Items With Fresh Start Cucumbers Due to the Potential for Salmonella Contamination
LAUREL, Md., May 22, 2025 (GLOBE NEWSWIRE) -- The Coastal Companies is issuing a voluntary recall of 17 products that were produced from cucumbers grown by Bedner Growers, Inc. and distributed by Fresh Start Produce Sales, Inc. due to the potential for Salmonella contamination. These products were distributed by East Coast Fresh in Laurel, MD and Hearn Kirkwood in Jessup, MD.
By Sysco Corporation · Via GlobeNewswire · May 22, 2025
KBR Signs Letter of Intent to Develop Spaceflight Food Lab at Exploration Park Near Johnson Space Center
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- KBR (NYSE: KBR), a leader in human spaceflight expertise for more than 60 years, has signed a letter of intent with ACMI Properties to grow KBR’s commercial space capabilities including a human spaceflight food laboratory at NASA’s Exploration Park, adjacent to Johnson Space Center. The 45,000 square-foot, Houston-based facility would serve the growing commercial low-Earth orbit (LEO) industry where tailorable astronaut food systems and solutions will be designed, tested, validated, produced, and integrated into customer mission environments.
By Kellogg Brown & Root LLC. · Via GlobeNewswire · May 22, 2025
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20%
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
-  63% response rate observed among 43 evaluable patients
By Merus N.V. · Via GlobeNewswire · May 22, 2025
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago, Illinois.
By Allogene Therapeutics, Inc. · Via GlobeNewswire · May 22, 2025
Daktronics to Participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28th
BROOKINGS, S.D., May 22, 2025 (GLOBE NEWSWIRE) -- Daktronics, Inc. (Nasdaq: DAKT), a leading global designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide today announced that Brad Wiemann, Interim Chief Executive Officer and Howard Atkins, Acting Chief Financial Officer will participate in the Craig-Hallum Capital Group’s 22nd Annual Institutional Investor Conference to be held Wednesday, May 28th, 2025 in Minneapolis, MN.
By Daktronics, Inc. · Via GlobeNewswire · May 22, 2025
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
ImCheck Reports High Remission Rates in AML Patientswith ICT01 Combination Therapy at ASCO 2025
By ImCheck Therapeutics SAS · Via GlobeNewswire · May 22, 2025
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. These data will be presented on Sunday, June 1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation during the “Lung Cancer – Non-Small Cell Metastatic” session from 9:00 AM-9:12 AM CDT (Abstract #8503).
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients living with multiple myeloma will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2025 European Hematology Association’s (EHA) Congress. Preliminary results from Phase 1 LB2102 and Phase 1 LB1908 ongoing dose-escalation studies in solid tumors, specifically lung and gastric cancers respectively, will also be featured in poster presentations at ASCO.
By Legend Biotech USA Inc. · Via GlobeNewswire · May 22, 2025
Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting
FLORENCE, Italy and NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present updated preliminary efficacy and safety results from the Phase 1b/2 ELEVATE study in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC). The ELEVATE study was designed to evaluate the safety and efficacy of oral-oral combination treatment options to overcome different resistance mechanisms observed in ER+/HER2- mBC and improve patient outcomes. Additionally, various other trial-in-progress updates will be presented, investigating elacestrant’s potential to become an endocrine therapy (ET) backbone across the spectrum of breast cancer. These data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
By Stemline Therapeutics, Inc. · Via GlobeNewswire · May 22, 2025
ROHM Develops Compact Surface-Mount Near-Infrared LEDs Featuring Industry-Leading Radiant Intensity
Santa Clara, CA and Kyoto, Japan, May 22, 2025 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced an expanded portfolio of surface-mount near-infrared (NIR) LEDs with new compact top-view types optimized for applications such as VR/AR devices, industrial optical sensors, and human detection sensors.
By ROHM Semiconductor · Via GlobeNewswire · May 22, 2025
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that results from the Company’s positive phase 3 clinical trial of aglatimagene besadenovec (CAN-2409) in patients with intermediate-to-high-risk localized prostate cancer will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 30 to June 3, 2025.
By Candel Therapeutics · Via GlobeNewswire · May 22, 2025
Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
Ingelheim, Germany, 22 May 2025 – Boehringer Ingelheim today announced that new clinical data from two early-stage trials targeting the signal regulatory protein α (SIRPα) innate immune checkpoint will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 - June 3, 2025, in Chicago, IL, USA. 
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events
By Adagene Inc. · Via GlobeNewswire · May 22, 2025
Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting
Novel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system in non-small cell lung cancer patient samples
By Avidicure · Via GlobeNewswire · May 22, 2025
Lyme Timber Receives the 2025 SFI Leadership in Conservation Award for Advancing Nature-Based Solutions in SFI-Certified Forests
MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- The Sustainable Forestry Initiative (SFI) is pleased to announce The Lyme Timber Company as the recipient of the 2025 SFI Leadership in Conservation Award. Lyme Timber, certified to the SFI Forest Management Standard, is being recognized for a longstanding commitment to advancing conservation outcomes across its land base. SFI specifically recognizes Managing Directors Peter Stein and Sean Ross for their instrumental leadership in partnering on meaningful conservation efforts related to biodiversity conservation, research-based forest management practices, and climate smart forestry.
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy
By Biodesix, Inc. · Via GlobeNewswire · May 22, 2025
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
First results to be presented in two ASCO oral presentations
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset
By Bicara Therapeutics Inc. · Via GlobeNewswire · May 22, 2025
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced multiple presentations related to its oncology programs at upcoming medical conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting, and the European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress.
By Zymeworks Inc. · Via GlobeNewswire · May 22, 2025
Cal Redwood Acquisition Corp. Announces Pricing of $200 Million Initial Public Offering
Menlo Park, CA, May 22, 2025 (GLOBE NEWSWIRE) -- Cal Redwood Acquisition Corp. (the “Company”) announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit on May 22, 2025. The units are expected to be listed for trading on the Nasdaq Global Market under the ticker symbol “CRAQU” beginning May 23, 2025. Each unit consists of one Class A ordinary share and one right to receive one tenth of a Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and rights will be listed on the Nasdaq Global Market under the symbols “CRA” and “CRAQR,” respectively. The offering is expected to close on May 27, 2025, subject to customary closing conditions.
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the “10-Q”) is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”).
By Onconetix, Inc. · Via GlobeNewswire · May 22, 2025
“Finish Line Campaign” Erases More than $83,000 of debt for Howard Community College Graduates, Continuing Students
COLUMBIA, Md., May 22, 2025 (GLOBE NEWSWIRE) -- Howard Community College (HCC) President Daria J. Willis today announced more than $83,000 of cleared institutional balances for graduating and continuing students at the institution. 
By Howard Community College · Via GlobeNewswire · May 22, 2025
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 22, 2025
China's First Laozi Digital Human Unveiled in Sanmenxia, Henan
The Organizing Committee of Sanmenxia Yellow River Cultural Tourism Festival
Guggenheim Second Quarter 2025 High Yield and Bank Loan Outlook: Credit Crossroads: Finding Value in an Era of Uncertainty
Relative value opportunities in volatile spread environment
ESET participates in operation to disrupt the infrastructure of Danabot infostealer
PRAGUE and BRATISLAVA, Czech Republic, May 22, 2025 (GLOBE NEWSWIRE) -- ESET has participated in a major infrastructure disruption of the notorious infostealer, Danabot, by the US Department of Justice, the FBI, and US Department of Defense’s Defense Criminal Investigative Service. U.S. agencies were working closely with Germany’s Bundeskriminalamt, the Netherlands' National Police, and the Australian Federal Police. ESET took part in the effort alongside Amazon, CrowdStrike, Flashpoint, Google, Intel471, PayPal, Proofpoint, Team Cymru and Zscaler. ESET Research, which has been tracking Danabot since 2018, contributed assistance that included providing technical analysis of the malware and its backend infrastructure, as well as identifying Danabot’s C&C servers. During that period, ESET analyzed various Danabot campaigns all over the world, with Poland, Italy, Spain and Turkey historically being one of the most targeted countries. The joint takedown effort also led to the identification of individuals responsible for Danabot development, sales, administration, and more.
By ESET · Via GlobeNewswire · May 22, 2025
Crown LNG Holdings Limited Discloses Receipt of NASDAQ Notice
LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- On May 19, 2025, Crown LNG Holdings Limited (the “Company”)  (NASDAQ: CGBS), received a letter (the “Letter”) from The NASDAQ Stock Market LLC (“NASDAQ”) indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the period ended December 31, 2024 (the “20-F”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with NASDAQ Listing Rule 5250(c)(1), which requires timely filing of all required financial reports with the SEC.
By Crown LNG · Via GlobeNewswire · May 22, 2025
Athene Holding Ltd. Declares Second Quarter 2025 Preferred Stock Dividends
WEST DES MOINES, Iowa, May 22, 2025 (GLOBE NEWSWIRE) -- Athene Holding Ltd. (“Athene”) announced that it has declared the following preferred stock dividends on its non-cumulative preferred stock (represented by depositary shares, each representing a 1/1,000th interest in a share of preferred stock), payable on June 30, 2025 to holders of record as of June 15, 2025.
By Athene Holding Ltd. · Via GlobeNewswire · May 22, 2025
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview.
By Bio-Path Holdings, Inc. · Via GlobeNewswire · May 22, 2025
Interpublic Declares Common Stock Dividend
New York, NY, May 22, 2025 (GLOBE NEWSWIRE) -- Interpublic Group (NYSE: IPG) today announced that the company’s Board of Directors has declared a quarterly dividend on IPG common stock of $0.33 per share, payable on June 16, 2025, to holders of record at the close of business on June 2, 2025.
UCTT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Ultra Clean Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 23 Deadline in Securities Class Action – UCTT
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 22, 2025
USAging and 50+ National Groups Call on Congress to Protect the Older Americans Act
Washington, DC, May 22, 2025 (GLOBE NEWSWIRE) -- USAging and more than 50 other national aging and health-focused organizations and enterprises have called upon Congress to protect the federal Older Americans Act (OAA) in a letter sent today to the leaders of the committees of jurisdiction for the OAA. The letter calls attention to a proposal to break apart OAA services under the Department of Health and Human Services (HHS) reorganization.
By USAging · Via GlobeNewswire · May 22, 2025
Uniti Group Inc. to Participate at the Goldman Sachs 10th Annual Leveraged Finance and Credit Conference
LITTLE ROCK, Ark., May 22, 2025 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its Senior Vice President, Chief Financial Officer and Treasurer, Paul Bullington, and Senior Vice President, Investor Relations & Treasury, Bill DiTullio, are scheduled to participate at the Goldman Sachs 10th Annual Leveraged Finance and Credit Conference on May 29, 2025 in Dana Point, CA.
By Uniti Group Inc. · Via GlobeNewswire · May 22, 2025
Everbright Digital Holdings Limited Announces Closing of Partial Exercise of Over-Allotment Option
HONG KONG, May 22, 2025 (GLOBE NEWSWIRE) -- Everbright Digital Holdings Limited (the “Company” or “Everbright”) (Nasdaq: EDHL), an integrated marketing solutions provider headquartered in Hong Kong, today announced that it has issued an additional 160,000 ordinary shares (the “Ordinary Shares”) at a price of US$4.00 per share for gross proceeds of approximately $640,000, before deducting underwriter discounts and other related expenses, pursuant to the partial exercise of the underwriter’s over-allotment option in connection with the Company’s previously announced initial public offering (the “Offering”). The option closing date was May 22, 2025. The ordinary shares began trading on the Nasdaq Capital Market on April 17, 2025, under the ticker symbol “EDHL”.
Quanex Building Products Announces Second Quarter 2025 Earnings Release and Conference Call Schedule
HOUSTON, TEXAS, May 22, 2025 (GLOBE NEWSWIRE) -- Quanex Building Products Corporation (NYSE: NX) (“Quanex” or the “Company”) today announced plans to release its second quarter 2025 results on Thursday, June 5, 2025, after trading closes on the New York Stock Exchange.
VALHI ANNOUNCES QUARTERLY CASH DIVIDEND AND RESULTS OF ANNUAL STOCKHOLDER MEETING
Dallas, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Valhi, Inc. (NYSE:  VHI) announced today that its board of directors has declared a regular quarterly dividend of eight cents ($0.08) per share on its common stock, payable on June 26, 2025 to stockholders of record at the close of business on June 9, 2025.
By Valhi, Inc. · Via GlobeNewswire · May 22, 2025
IBTA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ibotta, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – IBTA
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 22, 2025
SOUN DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages SoundHound AI, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – SOUN, SOUNW
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 22, 2025
Robbins LLP Reminds Elevance Health, Inc. Stockholders of the Class Action Against ELV – Contact Us for Information
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) --
By Robbins LLP · Via GlobeNewswire · May 22, 2025
GENFIT Reports First Quarter 2025 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025.1
By GENFIT S.A. · Via GlobeNewswire · May 22, 2025
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry
By Dianthus Therapeutics, Inc. · Via GlobeNewswire · May 22, 2025
SEI DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Solaris Energy Infrastructure, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 27 Deadline in Securities Class Action – SEI
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 22, 2025
ROSEN, A LEADING NATIONAL FIRM, Encourages Open Lending Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – LPRO
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · May 22, 2025
Codere Online Receives Delisting Notice from Nasdaq and Submits Appeal
Luxembourg, Grand Duchy of Luxembourg, May 22, 2025 - (GLOBE NEWSWIRE) Codere Online Luxembourg, S.A. (“Codere Online” or the “Company”) (Nasdaq: CDRO / CDROW), today announced that, on May 16, 2025, it received a staff determination letter (the "Letter"), from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company of the determination from the Nasdaq Staff (the "Staff") to delist the Company's securities from The Nasdaq Stock Market, given the Company had not filed its Form 20-F for the year ended December 31, 2024 (the “2024 Form 20-F”) in accordance with continued Listing Rule 5250(c)(1) (the “Public Reports Rule”). As previously reported, the Company’s delay in filing its 2024 Form 20-F is due to the fact that the finalization of the audit of the Company’s financial statements for the year ended December 31, 2024 has taken longer than expected following the engagement of the Company’s new independent registered public accounting firm on December 31, 2024 and the Company’s diligent efforts to finalize the Form 20-F for the year ended December 31, 2023, which the Company filed with the Securities and Exchange Commission (“SEC”) on May 1, 2025.